Katsuyuki Kiura

Summary

Affiliation: Okayama University
Country: Japan

Publications

  1. ncbi Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer
    K Kiura
    Second Department of Internal Medicine, Okayama University Medical School, Okayama, Japan
    Br J Cancer 89:795-802. 2003
  2. ncbi Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial
    Katsuyuki Kiura
    Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences and Okayama University Hospital, Okayama, Japan
    J Thorac Oncol 2:44-50. 2007
  3. ncbi A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer
    Katsuyuki Kiura
    Okayama Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences and Okayama University Hospital, Okayama, Japan
    J Thorac Oncol 3:386-93. 2008
  4. ncbi Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer
    Nobukazu Fujimoto
    Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital, Okayama 700 8558, Japan
    Acta Med Okayama 64:33-7. 2010
  5. ncbi A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer
    Masahiro Tabata
    Department of Medicine II, Okayama University Medical School, 2 5 1, Shikata cho, Okayama, 700 8558, Japan
    Cancer Chemother Pharmacol 60:1-6. 2007
  6. ncbi Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
    J Thorac Oncol 2:632-7. 2007
  7. ncbi Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer
    Shoichi Kuyama
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan
    J Thorac Oncol 3:477-82. 2008
  8. ncbi Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice
    Kadoaki Ohashi
    Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    Cancer Res 69:7088-95. 2009
  9. ncbi Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience
    Katsuyuki Hotta
    Department of Medicine II, Okayama University Medical School, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Acta Oncol 44:717-22. 2005
  10. ncbi A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705
    Hiroshige Yoshioka
    Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Okayama, Japan
    J Thorac Oncol 5:99-104. 2010

Collaborators

Detail Information

Publications125 found, 100 shown here

  1. ncbi Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer
    K Kiura
    Second Department of Internal Medicine, Okayama University Medical School, Okayama, Japan
    Br J Cancer 89:795-802. 2003
    ....
  2. ncbi Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial
    Katsuyuki Kiura
    Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences and Okayama University Hospital, Okayama, Japan
    J Thorac Oncol 2:44-50. 2007
    ..To determine the recommended dose and evaluate the response rate and toxicity of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for non-small cell lung cancer (NSCLC) patients with stage IIIB or IV...
  3. ncbi A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer
    Katsuyuki Kiura
    Okayama Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences and Okayama University Hospital, Okayama, Japan
    J Thorac Oncol 3:386-93. 2008
    ..Vandetanib was evaluated as a monotherapy in a randomized, double-blind, dose-finding study in Japan...
  4. ncbi Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer
    Nobukazu Fujimoto
    Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital, Okayama 700 8558, Japan
    Acta Med Okayama 64:33-7. 2010
    ..Triplet chemotherapy showed impressive survival data in our clinical trial, but proved too toxic for use in treating patients with NSCLC in the clinical practice...
  5. ncbi A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer
    Masahiro Tabata
    Department of Medicine II, Okayama University Medical School, 2 5 1, Shikata cho, Okayama, 700 8558, Japan
    Cancer Chemother Pharmacol 60:1-6. 2007
    ....
  6. ncbi Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
    J Thorac Oncol 2:632-7. 2007
    ..The aim of this study was to clarify its association. We also examined whether this association could be affected by previous gefitinib treatment...
  7. ncbi Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer
    Shoichi Kuyama
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan
    J Thorac Oncol 3:477-82. 2008
    ..The aim of this study was to evaluate their relationships...
  8. ncbi Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice
    Kadoaki Ohashi
    Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    Cancer Res 69:7088-95. 2009
    ..No fatal toxic events occurred in either group, and gefitinib inhibited tumorigenesis completely in this mouse model. These results suggest the utility of molecular targeted chemoprevention against nonsmoking-related lung cancer...
  9. ncbi Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience
    Katsuyuki Hotta
    Department of Medicine II, Okayama University Medical School, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Acta Oncol 44:717-22. 2005
    ..57, 95% confidence interval: 0.91-22.72, p = 0.0642). In this study, treatment with gefitinib appeared to be as safe and effective in elderly patients (aged 75 or older) with NSCLC as in non-elderly patients...
  10. ncbi A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705
    Hiroshige Yoshioka
    Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Okayama, Japan
    J Thorac Oncol 5:99-104. 2010
    ..The aim of this trial was to evaluate the efficacy and toxicity of erlotinib in Japanese patients with EGFR-wt tumors...
  11. ncbi Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines
    Keisuke Aoe
    Department of Internal Medicine, Okayama University Medical School, Okayama, Japan
    Anticancer Res 24:3893-7. 2004
    ..Accordingly, pretreatment with cisplatin will have an impact on the sensitivity to SN-38...
  12. ncbi Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, 2 5 1, Shikata cho, Okayama, 700 8558, Japan
    J Cancer Res Clin Oncol 135:117-23. 2009
    ..Smoking status also affects the responsiveness to gefitinib, but it has not been fully evaluated whether a sex difference exists in the influence of smoking on the efficacy of gefitinib in patients with lung adenocarcinoma...
  13. ncbi Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung
    Hiroshi Suehisa
    Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2 5 1 Shikata cho, Okayama, Japan
    J Clin Oncol 25:3952-7. 2007
    ..The present study evaluated whether the EGFR status could be used as a biologic predictor of the outcome of adjuvant chemotherapy with uracil-tegafur...
  14. ncbi Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer
    Shinobu Hosokawa
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Lung Cancer 66:107-13. 2009
    ..Moreover, the impact of downstream signaling of EGFR on clinical features in patients with non-small cell lung cancer (NSCLC) remains undetermined...
  15. ncbi Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation
    Katsuyuki Hotta
    Department of Medicine II, Okayama University Medical School, Okayama 700 8558, Japan
    Oncol Rep 17:313-7. 2007
    ..Our results indicate that senescence might be a major anti-tumor mechanism of gefitinib in these NSCLC cells regardless of the EGFR gene mutation status...
  16. ncbi Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice
    Daizo Kishino
    Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan
    Lung Cancer 65:284-9. 2009
    ..Our results suggest that gefitinib has a weak but significant chemopreventive effect with no carcinogenicity or pulmonary toxicity in A/J mice...
  17. ncbi DNA methylation in small lung adenocarcinoma with bronchioloalveolar carcinoma components
    Takafumi Kubo
    Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
    Lung Cancer 65:328-32. 2009
    ..021). Our results indicate the involvement of epigenetic alterations in the progression of adenocarcinoma with BAC components...
  18. ncbi Establishment of pemetrexed-resistant non-small cell lung cancer cell lines
    Dan Zhang
    Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Cancer Lett 309:228-35. 2011
    ..GARFT did not correlate with resistance to PEM. In summary, PEM-resistant cells remained sensitive to docetaxel, vinorelbine, 5-fluorouracil, and irinotecan. TS expression appeared to be associated with resistance to PEM...
  19. ncbi Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment
    Masaru Jida
    Departments of Cancer and Thoracic Surgery, Graduate School of Medicine, Okayama University, Kita ku, Okayama, Japan
    Cancer Sci 100:1931-4. 2009
    ..Thus, patients who have smoked less than 13 PY might be candidates for gefitinib treatment when EGFR mutation status cannot be determined...
  20. ncbi Multicyclic dose-intensive chemotherapy supported by autologous blood progenitor cell transplantation for relapsed small cell lung cancer
    Nobukazu Fujimoto
    Department of Internal Medicine II, Okayama University Medical School, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
    Anticancer Res 23:4229-32. 2003
    ..These results suggest the feasibility and effectiveness of multicyclic DI-CT and the usefulness of ABPCT as a treatment option for relapsed SCLC...
  21. ncbi A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study
    Masahiro Tabata
    Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
    Cancer Chemother Pharmacol 60:53-9. 2007
    ..We conducted a phase I/II study of triplet chemotherapy consisting of cisplatin (CDDP), docetaxel (DCT) and gemcitabine (GEM) in patients with advanced non-small-cell lung cancer (NSCLC)...
  22. ncbi Serum level of arginine-vasopressin influences the prognosis of extensive-disease small-cell lung cancer
    Shigeki Umemura
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700 8558, Japan
    J Cancer Res Clin Oncol 133:519-24. 2007
    ..The purpose of this study is to elucidate the influence of serum arginine-vasopressin (AVP) level on prognosis of extensive-disease small-cell lung cancer (ED-SCLC)...
  23. ncbi Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer
    Yoshiro Fujiwara
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Lung Cancer 52:99-103. 2006
    ..However, the relationship between EGFR mutation and adverse events of gefitinib is still unknown. The aim of this study was to evaluate its correlation...
  24. ncbi Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma
    Toshiyuki Kozuki
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine and Density, Okayama, Japan
    J Cancer Res Clin Oncol 131:147-51. 2005
    ..In addition, the evaluation of systemic and multimodality treatment strategies similar as in small cell lung cancer is worthy of consideration...
  25. ncbi The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants
    Shinichi Toyooka
    Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Okayama University, Okayama, Japan
    J Thorac Oncol 2:321-4. 2007
    ..However, our in vitro investigation did not explain the response observed in this particular patient. Further investigation is necessary to elucidate the mechanism of tumor sensitivity to EGFR tyrosine kinase inhibitors...
  26. ncbi Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
    J Thorac Oncol 5:179-84. 2010
    ..We investigated the incidence of ILD in Japanese patients treated with gefitinib or erlotinib...
  27. ncbi Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo
    Eiki Ichihara
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700 8558, Japan
    Cancer Res 69:5091-8. 2009
    ....
  28. ncbi Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group
    Katsuyuki Hotta
    Department of Medicine II, Okayama University Medical School, Okayama, Japan
    Cancer J 11:417-24. 2005
    ..The aim of this study was to retrospectively identify and evaluate these possible factors...
  29. ncbi Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007
    Yoshihiko Segawa
    Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University Hospital, Kitaku, Okayama, Japan
    J Clin Oncol 28:3299-306. 2010
    ..To demonstrate the efficacy of docetaxel and cisplatin (DP) chemotherapy with concurrent thoracic radiotherapy (TRT) for patients with locally advanced non-small-cell lung cancer (LA-NSCLC)...
  30. ncbi Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
    J Thorac Oncol 4:311-7. 2009
    ..We examined the association between differences in overall survival and time to progression (TTP) using a literature survey...
  31. ncbi Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter
    Kadoaki Ohashi
    Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Cancer Sci 99:1747-53. 2008
    ..This model will be useful for studying the mechanisms of carcinogenesis, chemoprevention, and acquired resistance to EGFR TKIs in lung cancer patients carrying activating EGFR mutations...
  32. ncbi Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer
    Naoyuki Nogami
    Department of Internal Medicine II, Okayama University Medical School, 2-5-1 Shikatacho, Okayama, Okayama Prefecture 700-8558, Japan
    Lung Cancer 45:85-91. 2004
    ..6 months. To confirm the effectiveness of this combination for advanced NSCLC which was suggested in the present study, a phase II study with the recommended doses (150 mg/m2 for CPT and 50-60 mg/m2 for DCT) is warranted...
  33. ncbi Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line
    Atsuko Ogino
    Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan
    Cancer Res 67:7807-14. 2007
    ..Thus, the balance of expression levels between gefitinib-sensitive or gefitinib-resistant EGFR may govern the response to gefitinib in lung cancer...
  34. ncbi Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung
    Toshiyuki Kozuki
    Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Lung Cancer 58:30-5. 2007
    ..Although EGFR mutations appeared to be partially associated with the early steps of adenocarcinoma development, such mutations may possibly occur randomly even in multiple lesions in a single patient...
  35. ncbi Fractionated administration of irinotecan and cisplatin for treatment of extensive-disease small-cell lung cancer: a phase II study
    Nagio Takigawa
    Department of Internal Medicine II, Okayama University Medical School, 2-5-1 Shikatacho, Okayama 700-8558, Japan
    Anticancer Res 23:557-60. 2003
    ..CONCLUSION: These results suggest that the dose intensity of CPT-11 may have a major role on the activity of SCLC in this combination...
  36. ncbi Detection of EGFR gene mutations using the wash fluid of CT-guided biopsy needle in NSCLC patients
    Hiroki Otani
    Department of Cancer and Thoracic Surgery, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    J Thorac Oncol 3:472-6. 2008
    ..In this study, we examined whether epidermal growth factor receptor (EGFR) mutations were detectable using a polymerase chain reaction-based assay and wash fluid of computed tomography (CT)-guided lung biopsy needles...
  37. ncbi Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results
    Isao Oze
    Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
    PLoS ONE 4:e7835. 2009
    ..The objective of the current investigation was to determine the time trends in outcomes for the patients in those trials...
  38. ncbi Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line
    Masakazu Chikamori
    Second Department of Internal Medicine, Okayama University Medical School, Division of Thoracic Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
    Anticancer Res 24:3911-6. 2004
    ..The SBC-3/SN-38 cells had decreased topo I and II activity compared to the parent cells. The SN-38-resistant cell line, SBC-3/SN-38, will be useful to elucidate the mechanism of action of the topo I inhibitors...
  39. ncbi Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer
    Junichi Soh
    Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
    Int J Cancer 119:2353-8. 2006
    ..As clinical importance, the EGFR mutation status in pleural fluid can be a biomarker for the favorable outcome of gefitinib-treated NSCLC cases...
  40. ncbi Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, 2 5 1, Shikata cho, Okayama, 700 8558, Japan
    Lung Cancer 62:236-41. 2008
    ..However, this has been criticized because the better survival in such subpopulation might be attributable simply to their favorable natural history, rather than any treatment effect...
  41. ncbi Isolated metastasis of lung cancer to the thyroid gland
    Masahiro Osawa
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Lung Cancer 58:156-8. 2007
    ..This is the first report to document an isolated recurrence of the lung cancer to the thyroid...
  42. ncbi Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer
    Junichi Soh
    Department of Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700 8558, Japan
    Int J Cancer 121:1162-7. 2007
    ....
  43. ncbi Successful treatment of limited disease-small cell lung cancer with multimodality treatment consisting of concurrent chemoradiotherapy, high-dose chemotherapy with autologous peripheral blood stem cell transplantation and surgical resection
    Katsuyuki Hotta
    Department of Medicine II, Okayama University Medical School, Okayama
    Intern Med 42:1223-7. 2003
    ..He has been alive without recurrence for seven years. This multimodality treatment appeared to be effective for this patient. However, further investigation is necessary to clarify the role of multimodality treatment...
  44. ncbi Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells
    Kammei Rai
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    Mol Cancer Ther 10:1720-7. 2011
    ..These findings indicate promising therapeutic applications of miR-7-expressing plasmids against EGFR oncogene-addicted lung cancers including T790M resistance by liposomal delivery...
  45. ncbi Non-BAC component but not epidermal growth factor receptor gene mutation is associated with poor outcomes in small adenocarcinoma of the lung
    Naruyuki Kobayashi
    Department of Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    J Thorac Oncol 3:704-10. 2008
    ..The purpose of this study was to identify risk factors for poor clinical outcome after surgical resection of small lung adenocarcinoma...
  46. ncbi Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer
    Kazuyo Miyatake
    Department of Internal Medicine II, Okayama University Medical School, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Anticancer Res 23:2829-36. 2003
    ..The prognostic significance of mutant p53 protein, p-glycoprotein (P-gp) and glutathione S-transferase-pi (GST-pi) in patients with unresectable non-small cell lung cancer (NSCLC) has not been established...
  47. ncbi The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer
    Shinichi Toyooka
    Department of Cancer and Thoracic Surgery, Okayama University, Okayama, Japan
    Clin Cancer Res 13:5763-8. 2007
    ..In this study, we extensively investigated the impact of sex and smoking on the EGFR mutation...
  48. ncbi Recent improvement in lung cancer screening: a comparison of the results carried out in two different time periods
    Takuji Kitajima
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan
    Acta Med Okayama 60:173-9. 2006
    ....
  49. ncbi Parathyroid hormone-related protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia
    Akio Hiraki
    Department of Medicine II, Okayama University Medical School, Okayama, Japan
    Cancer 95:1706-13. 2002
    ..In the current study, the authors examined the usefulness of PTH-rP measurement at the time of first presentation in the follow-up of lung carcinoma patients with TIH...
  50. ncbi Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
    J Thorac Oncol 2:402-7. 2007
    ..The association between the objective response to chemotherapy and survival has not yet been fully evaluated using large cohorts in advanced non-small cell lung cancer...
  51. ncbi Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status
    Keiichi Fujiwara
    Department of Internal Medicine II, Okayama University Medical School, 2 5 1 Shikatacho, Okayama, 700 8558, Japan
    Lung Cancer 40:73-6. 2003
    ..Iressa' is a trademark of the AstraZeneca group of companies...
  52. ncbi Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
    Cancer 109:939-48. 2007
    ..The objective of the current investigation was to determine the time trends in outcomes for the patients in those trials...
  53. ncbi Hypercalcemia-leukocytosis syndrome associated with lung cancer
    Akio Hiraki
    Department of Medicine II, Okayama University Medical School, Okayama, Japan
    Lung Cancer 43:301-7. 2004
    ..5% of cases over a 10 year interval...
  54. ncbi Serum hemoglobin level determined at the first presentation is a poor prognostic indicator in patients with lung cancer
    Keisuke Aoe
    Second Department of Medicine, Okayama University Medical School, Japan
    Intern Med 44:800-4. 2005
    ..CONCLUSION: Anemia observed at the first presentation is an independent poor prognostic indicator in patients with lung cancer...
  55. ncbi A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer
    Nagio Takigawa
    Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
    Lung Cancer 71:60-4. 2011
    ..1-15.8 months) with a median follow-up time of 27.9 months. These results indicate that concurrent treatment with S-1 and thoracic radiation is a feasible option for NSCLC in the elderly. A phase II study is currently under way...
  56. ncbi Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer
    Katsuyuki Hotta
    Department of Medicine II, Okayama University Medical School, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    J Clin Oncol 22:3852-9. 2004
    ..We therefore did a meta-analysis of trials that compared cisplatin-based chemotherapy with carboplatin-based chemotherapy...
  57. ncbi Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007
    Nagio Takigawa
    Department of Respiratory Medicine, Okayama University Hospital, Kitaku, Okayama, Japan
    J Thorac Oncol 6:1087-91. 2011
    ..The Okayama Lung Cancer Study Group (OLCSG) 0007 trial with patients up to 75 years showed that with concurrent RT, docetaxel and cisplatin (DP) chemotherapy was an alternative to mitomycin C, vindesine, and cisplatin (MVP) chemotherapy...
  58. ncbi A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer
    Katsuyuki Hotta
    Departmnet of Internal Medicine II, Okayama University Medical School, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Lung Cancer 45:77-84. 2004
    ....
  59. ncbi Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine
    Yoshiro Fujiwara
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    Anticancer Drugs 19:431-3. 2008
    ..These findings indicate that single-agent gemcitabine is one of the few chemotherapeutic agents effective for palliation in patients with sarcomatoid renal cell carcinoma, even those with poor performance status...
  60. ncbi Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer
    Michio Inukai
    Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan
    Cancer Res 66:7854-8. 2006
    ....
  61. ncbi Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation
    Akiko Uchida
    Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Okayama 700 8558, Japan
    Cancer Sci 98:357-63. 2007
    ....
  62. ncbi A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors
    Tsuyoshi Kodani
    Department of Internal Medicine II, Okayama University Medical School, 2-5-1 Shikatacho, Okayama 700-8558, Japan
    Lung Cancer 36:313-9. 2002
    ..CONCLUSION: This study suggested the survival advantage of the VIP regimen over the VP regimen for treatment of patients with advanced NSCLC...
  63. ncbi Being overweight influences the development of hepatic dysfunction in Japanese patients with non-small-cell lung cancer undergoing cytotoxic chemotherapy
    Yoshiro Fujiwara
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    Lung Cancer 55:343-8. 2007
    ..The aim of this study was to identify risk factors for hepatic dysfunction during cytotoxic chemotherapy in Japanese patients with non-small-cell lung cancer (NSCLC)...
  64. ncbi Successful treatment of a patient with gastric and duodenal metastases from large cell carcinoma of the lung with carboplatin and gemcitabine
    Kadoaki Ohashi
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama, 700-8558, Japan
    Anticancer Res 26:4695-6. 2006
    ..Although the prognosis for patients with gastrointestinal metastases from lung cancer tends to be extremely poor, treatment with chemotherapy and a metastasectomy have resulted in this patient, achieving a long survival...
  65. ncbi Risk of neutropenic fever and early infectious complications after autologous peripheral blood stem cell transplantation for malignant diseases
    Keiko Fujii
    Second Department of Internal Medicine, Okayama University Medical School, Japan
    Int J Hematol 76:186-91. 2002
    ..Although the clinical indications for auto-PBSCT can be extended to elderly patients, thorough precautions should be taken against infectious complications during the pre-engraftment phase...
  66. ncbi MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors
    Takafumi Kubo
    Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
    Int J Cancer 124:1778-84. 2009
    ..Our results indicated that MET amplification was present in untreated NSCLC and EGFR mutation or MET amplification activated MET protein in NSCLC...
  67. ncbi Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line
    Hiroyuki Kohara
    Department of Internal Medicine II, Okayama University Medical School, Okayama 700 8558, Japan
    Clin Cancer Res 8:287-92. 2002
    ....
  68. ncbi Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study
    H Ueoka
    Second Department of Medicine, Okayama University Medical School, Japan
    Br J Cancer 79:984-90. 1999
    ..Diarrhoea became a dose-limiting toxicity. The objective response rates were 76% for NSCLC and 100% for SCLC. The recommended dose of CPT-11 and CDDP in a phase II study will be 50 mg m(-2) and 60 mg m(-2) respectively...
  69. ncbi Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group
    H Ueoka
    Department of Internal Medicine II, Okayama University Medical School, 2 5 1 Shikatacho, Okayama, 700 8558, Japan
    Br J Cancer 85:9-13. 2001
    ..Grade 3 or 4 diarrhoea was experienced in 25.0%, but manageable by conventional therapy. In conclusion, fractionated administration of CPT-11 and CDDP was highly effective for advanced NSCLC with manageable toxicities...
  70. ncbi Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy
    Haruyuki Kawai
    Second Department of Medicine, Okayama University Medical School, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
    Lung Cancer 35:305-14. 2002
    ..A pair of cell lines will be useful to elucidate resistant mechanisms of cisplatin in heterogeneous lung cancer cells...
  71. ncbi Intramedullary spinal cord recurrence after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation for limited-disease small cell lung cancer
    N Fujimoto
    Department of Internal Medicine II, Okayama University Medical School, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Lung Cancer 30:145-8. 2000
    ..At this time of reporting, he is doing well without recurrence. This case indicates that intramedullary spinal cord is one of the recurrence sites implicated after HDCT and PCI in LD-SCLC...
  72. ncbi Induction chemoradiotherapy prior to surgery for non-small cell lung cancer invading the left atrium
    Shinichi Toyooka
    Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Eur J Cardiothorac Surg 33:315-6. 2008
    ..Our case suggests that induction chemoradiotherapy prior to surgery can be an appropriate strategy among carefully selected patients with non-small cell lung cancer invading the left atrium...
  73. ncbi Tandem high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation for recurrent soft tissue sarcoma
    Teruhiko Kozuka
    Second Department of Internal Medicine, Okayama University Medical School, 2 5 1 Shikatacho, Okayama 700 8558, Japan
    Anticancer Res 22:2939-44. 2002
    ..The role of high-dose chemotherapy (HDC) with hematopoietic stem cell support in this disease has not been established...
  74. ncbi Desire for information and involvement in treatment decisions: lung cancer patients' preferences and their physicians' perceptions: results from Okayama Lung Cancer Study Group Trial 0705
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, Kitaku, Okayama, Japan
    J Thorac Oncol 5:1668-72. 2010
    ..The impact of demographic and psychosocial characteristics on the decisional role of patients is also examined...
  75. ncbi Interleukin-12 augments cytolytic activity of peripheral blood mononuclear cells against autologous lung cancer cells in combination with IL-2
    Akio Hiraki
    Department of Medicine II, Okayama University Medical School, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Lung Cancer 35:329-33. 2002
    ..These results suggest that an administration of IL-12 in combination with IL-2 may be a useful therapeutic option for solid tumors...
  76. ncbi Primary signet-ring cell carcinoma of the lung with histochemical characterization
    Akio Hiraki
    Departments of Medicine II, Okayama University Medical School, Japan
    Anticancer Res 22:1079-81. 2002
    ..Although the patient achieved only a minor response after systemic chemotherapy, he has been doing well, without any further treatment, for 33 months after diagnosis...
  77. ncbi Pseudoprogression of lung cancer after concomitant chemoradiotherapy
    Eiki Ichihara
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2 5 1 Shikata, Okayama, Okayama 700 8558, Japan
    Jpn J Clin Oncol 38:140-2. 2008
    ..We herein report a rare case of lung cancer showing a pathological complete response despite re-enlargement of tumour lesion...
  78. ncbi An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer
    Katsuyuki Hotta
    Department of Medicine II, Okayama University Medical School, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Lung Cancer 46:61-76. 2004
    ..The aim of the present study was to identify elderly-specific clinical trials for advanced non-small cell lung cancer (NSCLC) and to clarify the study design and patient characteristics entered of each of these trials...
  79. ncbi Thrombocytosis as a useful prognostic indicator in patients with lung cancer
    Keisuke Aoe
    Second Department of Medicine, Okayama University Medical School, Higashi kiwa, Ube, Yamaguchi, Japan
    Respiration 71:170-3. 2004
    ..Thrombocytosis can accompany various cancers including lung cancer. This finding has recently been suggested to indicate poor prognosis...
  80. ncbi Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell lung cancer
    Katsuyuki Hotta
    Department of Respiratory Medicine, Okayama University Hospital, Japan
    Curr Opin Oncol 18:144-50. 2006
    ..This review will focus on recent clinical trials for adjuvant chemotherapy, and will help to interpret the applicability of these results to daily clinical practice...
  81. ncbi Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer
    Katsuyuki Hotta
    Department of Medicine II, Okayama University Medical School, 2 5 1, Shikata cho, Okayama, 700 8558, Japan
    Anticancer Res 25:2429-34. 2005
    ..Combination chemotherapy of irinotecan and amrubicin for advanced non-small cell lung cancer (NSCLC) has not been fully evaluated. To determine the maximum-tolerated dose (MTD), a phase I study in patients with advanced NSCLC was conducted...
  82. ncbi Pancreatic enzyme supplement improves dysmotility in chronic pancreatitis patients
    Takaaki Mizushima
    Department of Clinical Laboratory Medicine, Okayama University Medical School, Okayama, Japan
    J Gastroenterol Hepatol 19:1005-9. 2004
    ..The authors tested whether oral pancreatic enzymes can improve the dysmotility or not...
  83. ncbi Allogeneic peripheral blood stem cell transplantation in 23 adult patients with hematologic malignancies: a single-center experience
    K Takenaka
    Department of Internal Medicine II, Okayama University Medical School, Japan
    Int J Hematol 72:362-70. 2000
    ..Six of the 23 patients (26%) developed relapse at a median 81 days (range, 38-160 days) posttransplantation. Further study is needed to assess the precise benefits of alloPB-SCT compared with allogeneic bone marrow transplantation...
  84. ncbi High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56+ natural killer cell lymphomas
    K Takenaka
    Second Department of Internal Medicine, Okayama University Medical School, Japan
    Leuk Lymphoma 42:1297-303. 2001
    ....
  85. ncbi Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience
    K Hotta
    Department of Medicine II, Okayama University Medical School, Okayama
    Ann Oncol 16:1817-23. 2005
    ....
  86. ncbi Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials
    K Hotta
    Department of Medicine II, Okayama University Medical School, 2 5 1, Shikata cho, Okayama, 700 8558, Japan
    Ann Oncol 15:1782-9. 2004
    ..The aim of this study was to evaluate the effectiveness of platinum for advanced NSCLC by carrying out a meta-analysis of trials that compared platinum-based doublets with single new agent therapy alone...
  87. ncbi Tumor-specific cytotoxic T lymphocyte responses against chondrosarcoma with HLA haplotype loss restricted by the remaining HLA class I allele
    A Hiraki
    Department of Medicine II, Okayama University Medical School, Okayama 700 8558, Japan
    Biochem Biophys Res Commun 286:786-91. 2001
    ..Tumor specific immunotherapy can be applied to the treatment of malignancies, even if HLA expression is partially lost...
  88. ncbi Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer
    K Hotta
    Department of Respiratory Medicine, Okayama University Hospital, 2 5 1, Shikata cho, Okayama, Japan
    Ann Oncol 20:829-34. 2009
    ....
  89. ncbi An alteration of ganglioside composition in cisplatin-resistant lung cancer cell line
    K Kiura
    Second Department of Medicine, Okayama University Medical School, Japan
    Anticancer Res 18:2957-60. 1998
    ..SBC-3/CDDP cells showed a marked increase in ganglioside GM3. These findings suggest that the alteration of ganglioside composition may be actively involved in the acquisition of drug-resistance...
  90. ncbi Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer
    N Takigawa
    Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700 8558, Japan
    Br J Cancer 95:1142-4. 2006
    ..9 years. The incidence of SPC was 2.4 per 100 patient-years (95% confidence interval: 1.0-4.9)...
  91. ncbi Cytomegalovirus enteritis after autologous peripheral blood stem cell transplantation
    T Kozuka
    Second Department of Internal Medicine, Okayama University Medical School, Japan
    Ann Hematol 80:617-9. 2001
    ..However, our case indicates that CMV infection must be considered as a differential diagnosis in cases of unexplained hemorrhagic enteritis following autologous PBSCT...
  92. ncbi Successful treatment with concurrent chemoradiotherapy followed by surgery for a patient with thymic adenocarcinoma
    M Shimono
    Department of Internal Medicine II, Okayama University Medical School, Japan
    Anticancer Res 21:2519-22. 2001
    ..He then underwent surgical resection of the remaining mass. However, pathologic examination of the resected mass revealed no malignant cells. The patient is doing well without symptoms or signs of relapse 53 months after diagnosis...
  93. ncbi Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N(2) non-small cell lung cancer
    H Date
    Department of Surgery II, Okayama University School of Medicine, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Br J Cancer 86:530-3. 2002
    ..We conclude that the surgical resection after induction chemotherapy with cisplatin and irinotecan is feasible, and associated with low morbidity and high respectability...
  94. ncbi Combination of nedaplatin and vindesine for treatment of relapsed or refractory non-small-cell lung cancer
    N Takigawa
    Department of Internal Medicine, National Shikoku Cancer Center Hospital, Matsuyama, Japan
    Cancer Chemother Pharmacol 46:272-8. 2000
    ..A phase II study of nedaplatin and vindesine was conducted to evaluate their efficacy and safety for treatment of relapsed or refractory non-small-cell lung cancer (NSCLC)...
  95. ncbi Generation of cytotoxic T lymphocytes against autologous lung cancer cells resistant to apoptosis
    A Hiraki
    Department of Immunology, Okayama University Medical School, Japan
    Anticancer Res 21:2561-7. 2001
    ..The tumor cell line established after chemotherapy was apoptosis-resistant, but was sensitive to cytotoxicity of CTL. CONCLUSION: CTL-based immunotherapy may be one of the candidates for future therapies against NSCLC...
  96. ncbi Comparison of antitumor activity of new anthracycline analogues, ME2303, KRN8602, and SM5887 using human lung cancer cell lines
    N Takigawa
    Second Department of Medicine, Okayama University Medical School, Japan
    Acta Med Okayama 46:249-56. 1992
    ..3-fold to ME2303. In conclusion, ME2303 was found to be the most potent agent among drugs tested for the treatment of lung cancer, and KRN8602 can be expected to be beneficial for the treatment of drug-resistant small cell lung cancer...
  97. ncbi Induction of urokinase-type plasminogen activator by the anthracycline antibiotic in human RC-K8 lymphoma and H69 lung-carcinoma cells
    T Kiguchi
    Second Department of Medicine, Okayama University Medical School, Okayama, Japan
    Int J Cancer 93:792-7. 2001
    ..Therefore, by upregulating uPA expression, the anthracycline may influence many biologic cell functions mediated by the uPA/plasmin system...
  98. ncbi Lamivudine and glycyrrhizin for treatment of chemotherapy-induced hepatitis B virus (HBV) hepatitis in a chronic HBV carrier with non-Hodgkin lymphoma
    K Matsuo
    Second Department of Internal Medicine Okayama University, Medical School, 2 5 1 Shikata cho, Okayama, Japan
    Leuk Lymphoma 41:191-5. 2001
    ..This experience suggests that lamivudine combined with glycyrrhizin may be effective for controlling HBV replication and treating chemotherapy-induced HBV hepatitis in chronic HBV carriers with NHL...
  99. ncbi Evaluation of various cytological examinations by bronchoscopy in the diagnosis of peripheral lung cancer
    M Kawaraya
    Department of Respiratory Medicine, Okayama Institute of Health and Prevention, 408 1 Hirata, Okayama, Okayama 700 0952, Japan
    Br J Cancer 89:1885-8. 2003
    ..0001). Our results indicate that cytological examinations of the imprints of biopsy samples and the rinse fluids of the forceps and the brush improve the efficacy of fibreoptic bronchoscopy in the diagnosis of peripheral lung cancer...
  100. ncbi The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer
    Shuji Ichihara
    Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2 5 1 Shikata cho, Okayama 700 8558, Japan
    Int J Cancer 120:1239-47. 2007
    ..Our findings also suggest that the CA-SSR1 length may influence the clinical outcome in patients with a drug-sensitive EGFR mutation...
  101. ncbi [A successful case of lower gingival cancer with pulmonary metastases by adjuvant chemotherapy including paclitaxel, cisplatin and 5-fluorouracil following a surgical procedure]
    Goichi Tsukamoto
    Dept of Oral and Maxillofacial Surgery, Biopathological Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutic Sciences
    Gan To Kagaku Ryoho 34:597-600. 2007
    ..After that, there is no evidence of pulmonary recurrence for more than six years...